8-K: Regenerex Pharma CFO Suspended Amidst Review

Regenerex Pharma suspends CFO Kenneth Perry pending review of financial oversight and governance concerns, appointing Don E. Ray as interim CFO.

Summary

• Regenerex Pharma, Inc. has placed its Chief Financial Officer, Kenneth Perry, on administrative suspension leave with pay, effective March 31, 2026.
• The suspension is due to concerns regarding compliance with board directives, financial oversight, corporate governance, and financial reporting processes.
• Mr. Perry will continue to receive his salary and benefits during the suspension, which is subject to ongoing review with no final determinations made.
• Don E. Ray has been appointed as the Interim Chief Financial Officer, effective April 1, 2026, for an initial 90-day term with an annual salary of $150,000.
• Mr. Ray brings extensive experience in accounting and financial advisory roles, including previous interim CFO positions and work with public and private companies.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the serious nature of the concerns leading to the CFO's suspension, indicating potential internal control and governance issues.

Positives

• The company has proactively addressed concerns by suspending the CFO and initiating a review.
• An experienced interim CFO, Don E. Ray, has been appointed to ensure continuity in financial operations.
• Mr. Perry will continue to receive his salary and benefits, mitigating immediate financial hardship for him.
• The company emphasizes that the review is ongoing and no final determinations have been made, suggesting a fair process.

Negatives

• The suspension of the CFO indicates significant concerns regarding financial oversight, corporate governance, and reporting.
• The ongoing review suggests potential underlying issues that could impact the company's financial health and reputation.
• The appointment of an interim CFO for a 90-day term implies uncertainty about the duration of the review and the future of the CFO role.

Risks

• Potential for further findings during the ongoing review that could lead to more serious consequences.
• Reputational damage due to concerns about financial reporting and corporate governance.
• Disruption to financial operations and strategic planning during the interim CFO period.
• Possible impact on investor confidence and stock price due to the uncertainty surrounding the CFO's situation and the ongoing review.

Future Outlook

The filing does not contain specific forward-looking statements or guidance. The future outlook is contingent on the outcome of the ongoing review concerning the former CFO and the company's financial reporting and governance processes.

Management Comments

• The Board's decision was based on identified concerns relating to, among other matters, compliance with Board directives, financial oversight, corporate governance, and the Company's financial reporting processes and internal controls.
• The Company emphasizes that the review remains ongoing, and no final determinations have been made with respect to the matters described above.

Industry Context

StockSavvy.ai notes that executive suspensions, particularly for CFOs, often signal significant internal control or financial reporting issues. This event, if related to broader compliance or governance weaknesses, could be a red flag for investors in the pharmaceutical sector, where regulatory scrutiny is high.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact on stock price due to uncertainty and concerns about governance and financial reporting. Increased scrutiny on management's actions.
• Employees: Potential uncertainty regarding company stability and future leadership. Impact on morale.
• Creditors: May seek reassurance regarding the company's financial stability and reporting integrity.

Next Steps

• Completion of the ongoing review into compliance with Board directives, financial oversight, corporate governance, and financial reporting processes.
• Potential determination of further actions based on the review's findings.
• The interim CFO's 90-day initial term will be evaluated.

Key Dates

Recommendation

The suspension of the CFO and the ongoing review into governance and financial reporting raise significant concerns. While an interim CFO is in place, the uncertainty surrounding the investigation warrants a cautious 'hold' approach until more clarity is provided on the findings and their implications.

Keywords

Regenerex Pharma, CFO Suspension, Interim CFO, Kenneth Perry, Don E. Ray, Corporate Governance, Financial Reporting, Administrative Leave